Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and ...

Fintel reports that on August 5, 2025, Jefferies downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX) from Buy ...

Reports Q2 revenue $0 vs. $0 last year. As of June 30, Lava had cash, cash equivalents, and short-term investments of $56.2M vs. $76.6M as of ...

XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

LAVA Therapeutics (LVTX) stock gains as XOMA Royalty (XOMA) agrees to acquire the company for up to $1.24/share plus contingent value rights. Read more here.

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...